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Abstract: The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regu-
late the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research 
to biotechnology and gene therapy applications. These systems are based on regulatory elements that 
control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silenc-
ing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycy-
cline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construc-
tion of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in 
eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activ-
ity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA vari-
ants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low 
dox level can be reached, such as the brain. 
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1. INTRODUCTION 
Gene therapy applications can be complicated by adverse 
side or off-target effects of the transgene product. The ability 
to turn transgene expression on and off or to modulate the 
expression level may therefore significantly improve the 
safety of gene therapy approaches. Several regulatory 
mechanisms have been developed that allow both quantita-
tive and temporal control of gene expression in eukaryotic 
cells by an exogenous effector molecule [1]. We here focus 
on the Tet-Off and Tet-On systems that allow modulation of 
a gene-of-interest (G.O.I.) by administration or withdrawal 
of tetracyclines [2-4]. Tetracyclines constitute a diverse fam-
ily of chemical compounds with 4 hydrocarbon rings and 
different functional groups. The prototype tetracycline (Tc) 
and derivatives like doxycycline (dox) have been widely 
used in humans as antibiotic. The Tet-Off and Tet-On sys-
tems are based on the Tet repressor protein (TetR) and tet 
operator (tetO) DNA elements that control the Tn10-encoded 
tetracycline resistance operon of Escherichia coli.  
1.1. The Bacterial Tet Operon 
Tetracyclines are antibiotics that bind to the bacterial 30S 
ribosomal subunit and inhibit bacterial protein synthesis and 
growth. Bacteria have developed different mechanisms of 
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tetracycline resistance: tetracycline efflux, ribosome protec-
tion and tetracycline modification [5]. In Gram-negative bac-
teria, tetracycline resistance is mostly mediated by efflux of 
the drug by the membrane protein TetA [6, 7] and the TetA 
level is controlled by the tetracycline-responsive repressor 
protein TetR. In the Tn10-encoded Tet operon, the tetA and 
tetR genes are oriented in opposite direction and their ex-
pression is regulated at the transcription level by a shared 
regulatory region (Fig. 1A). This regulatory region consists 
of overlapping promoters PA and PR1/PR2 (driving tetA and 
tetR transcription, respectively) and two superimposed tetO 
operator sequences [7, 8]. The TetR proteins form dimers 
that recognize and bind the tetO elements, thus suppressing 
the activity of the PA and PR promoters and shutting off TetA 
and TetR production [9]. The high affinity of TetR for the 
tetO sequence allows efficient repression of TetA, which is 
important because even low TetA levels are disadvantageous 
for bacterial cells in the absence of tetracycline [10]. Binding 
of tetracycline triggers a conformational change in the TetR 
dimer that prevents tetO binding. As a consequence, TetR 
will no longer suppress the PA and PR promoters and TetA 
and TetR will be produced. The high affinity of TetR for the 
tetracycline allows activation of TetA production at very low 
tetracycline levels that do not yet block protein synthesis [4]. 
The low affinity of TetR for non-operator sequences results 
in a high specificity, which implies that TetR can be used to 
selectively regulate transgene expression in organisms with 
much larger genomes than bacteria [7].  
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1.2. The Eukaryotic Tet-Off System 
Gossen et al. described in 1992 how the TetR and tetO 
components of the Tn10-encoded Tet operon can be used to 
develop a regulatory mechanism for controlled gene expres-
sion in mammalian cells. In this Tet-Off system (Fig. 1B), 
the 127-amino acid (127-aa) transcription activation domain 
(AD) of the herpes simplex virus VP16 protein was fused to 
the 207-aa TetR, which resulted in the tetracycline-
controlled transcriptional activator (tTA) [11]. Furthermore, 
a tetracycline-responsive promoter (Ptet) was constructed by 
fusing 7 tetO sequences to a minimal TATA-box containing 
eukaryotic promoter. This promoter sequence was derived 
from the CMV immediate early gene and lacked enhancer 
sequences. In the absence of tetracycline, tTA dimers will 
bind the tetO sites in Ptet and activate expression of the 
downstream positioned transgene [11]. Tc or dox binding 
induces a conformational change in the TetR domain of tTA 
that prevents tetO binding, thus switching gene expression 
off.  
1.3. The Eukaryotic Tet-On System 
If only transient expression of the gene-of-interest is 
aimed for, a disadvantage of the Tet-Off system is that Tc or 
dox has to be administered continuously outside this small 
time window, while long-term exposure to these effectors is 
often undesirable. Another disadvantage is that the tetracy-
cline has to be removed to activate gene expression. Al-
though this can be achieved relatively easily in small cell 
culture experiments by thorough washing of the cells and 
replacement of the culture medium, it is more problematic 
when large cell cultures are used and in animal experiments. 
In vivo, the biological half-life of the effector will determine 
the kinetics of induction. In 1995, Gossen et al. developed 
the Tet-On system (Fig. 1C), a regulatory system that allows 
activation of gene expression by the addition - instead of 
removal - of dox [12]. For this, random mutation and pheno-
type screening in E. coli were first used to select a TetR vari-
ant that functions in a reverse fashion, i.e. binds tetO in the 
presence and not in the absence of the effector. This reverse-
TetR (rTetR) differed at four amino acid positions from the 
original protein (Fig. 2). The high resolution TetR-Tc crystal 
structure that is available for the TetR class D protein, which 
shares 63% sequence identity with the TetR class B protein 
that was used to construct the Tet systems, indicated that 
these amino acids do not contact Tc directly and are not part 
of the tetO DNA binding domain (DBD). Subsequent fusion 
of the VP16 activation domain resulted in a reverse-tTA 
(rtTA) that binds Ptet and activates transcription exclusively 
in the presence of dox [12]. Unfortunately, the 4 amino acid
 
Fig. (1). Tc-controlled regulation of gene expression. (A) Tn10 tet operon. In E. coli, TetR binds as a dimer to the tetO1 and tetO2 sites in 
the Tn10 tet operon. This interaction blocks the activity of the underlying promoters (PA, PR1 and PR2) and inhibits transcription of the tetA 
and tetR genes. Binding of Tc or dox triggers a conformational switch in TetR that prevents tetO binding and results in the activation of TetA 
and TetR production. (B) The Tet-Off system. Fusion of TetR to the activation domain of the herpes simplex virus VP16 protein (VP16 AD) 
resulted in the Tc-controlled transcriptional activator (tTA). Binding of tTA to the Ptet promoter that consists of 7 tetO sequences fused to a 
minimal TATA-box containing eukaryotic promoter, activates expression of the downstream positioned gene-of-interest (G.O.I.) Binding of 
Tc or dox induces a conformational change in the TetR domain of tTA, which prevents tetO binding and switches gene expression off. (C) 
The Tet-On system. The reverse-tTA (rtTA) variant exhibits a reverse phenotype and does not bind tetO in the absence of an effector. Bind-
ing of dox triggers a conformational switch in rtTA, which allows tetO binding. Subsequent activation of the Ptet promoter drives expression 
of the downstream positioned gene. The initial version of rtTA had a low affinity for Tc and was not activated by this compound. 
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Fig. (2). Construction and optimization of the Tet-On system. (A) Schematic overview of the development of rtTA variants by rational 
design, random mutation and screening in E. coli and yeast (S. cerevisiae) and virus evolution in human cells. See text for details. The color 
of the TetR domain reflects the effector responsiveness (white, low Tc/dox response; black, high Tc/dox response). (B) Mutations in the TetR 
moiety and activation domain (AD) in different rtTA variants. The activity of the variants indicated with an arrow was directly compared in 
transiently transfected and stably transduced cells (Figs. 5, 6). 
substitutions in the TetR domain of rtTA that resulted in the 
reverse phenotype significantly reduced the sensitivity to-
ward the effector. As a consequence, rtTA was only poorly 
activated by Tc and required 100-fold more dox for maximal 
induction than what is needed for complete tTA inhibition 
[3].  
2. IMPROVEMENTS OF THE Tet-ON SYSTEM 
Optimal control of gene expression requires a Tet-On 
system with low background activity in the absence of dox 
and high activity in the presence of the effector. Important 
characteristics of the Tet-On system that influence back-
ground activity are the intrinsic, rtTA-independent activity of 
the pTet promoter, which is due to the presence of binding 
sites for cellular transcription factors, and the residual bind-
ing of rtTA to pTet in the absence of dox. The pTet promoter 
has been optimized through systematic modification, which 
resulted in novel promoter configurations that minimized 
intrinsic background activity while maintaining high induced 
expression [13, 14]. We will here describe the different 
strategies that have been used to improve the rtTA compo-
nent of the Tet-On system. 
Random mutagenesis of tTA followed by a functional 
screen for the reverse, dox-inducible phenotype in the yeast 
S. cerevisiae resulted in a novel rtTA variant, rtTA-S2, with 
4 amino acid substitutions in the TetR domain [15] (Fig. 2). 
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Two of the selected mutations (E19G in the DBD and A56P 
in the helix connecting the DBD with the core) were shown 
to reverse the phenotype, whereas the other mutations 
(D148E and H179R; positioned in the core, close to amino 
acids involved in effector binding and dimerization) en-
hanced the activity. Notably, all 4 amino acid changes dif-
fered from the rTetR mutations identified in the TetR muta-
tion/screening in E. coli, which were used for the develop-
ment of the first generation rtTA. A second round of 
mutagenesis and screening in S. cerevisiae yielded an addi-
tional DBD mutation (S12G) that increased the activity of 
rtTA-S2, in particular at low dox concentrations. The rtTA-
S2 variant and the S12G-mutated derivative rtTA-M2 were 
optimized by substitution of the 127-aa VP16 AD with 3 
repeats of the 12-aa minimal AD. This AD minimization 
removed potential targets for interactions with cellular tran-
scription factors, which reduced toxic squelching effects 
[16]. This truncation of the VP16 moiety also reduced the 
number of potential epitopes that may elicit a cellular im-
mune response in animal applications. Furthermore, the rtTA 
coding sequence was optimized for human codon usage and 
putative toxic mRNA elements were removed: splice donor 
and acceptor sites, motifs for endonuclease cleavage sites 
and sequences inducing hairpin structures [15]. These studies 
resulted in the rtTA2
S
-S2 and rtTA2
S
-M2 variants that dem-
onstrated increased stability and reduced background activity 
in the absence of dox when compared with the original rtTA. 
The rtTA2
S
-M2 variant (a.k.a. Tet-On Advanced, Clontech) 
demonstrated the highest sensitivity toward dox and func-
tioned at a 10-fold lower dox concentration than the original 
rtTA and rtTA-S2. However, further improvement of the 
Tet-On system was desirable. For example, rtTAs with an 
increased dox-sensitivity will require less dox, which will 
avoid cellular side effects due to the inhibitory effect of high 
tetracycline levels on mitochondrial translation [17]. Fur-
thermore, such rtTAs will be beneficial for applications in 
tissues where a relatively low dox level can be reached, such 
as the brain. 
3. GENE THERAPY APPLICATIONS IN THE CNS 
REQUIRE A DOX-SENSITIVE Tet-ON SYSTEM 
Whereas immune reactions directed against the viral vec-
tor or transgene may limit systemic gene therapy applica-
tions [18], gene therapy in immunologically-privileged sites, 
like the central nervous system (CNS), are not restricted by 
such deleterious immune responses [19]. Unfortunately, the 
main neurodegenerative diseases, i.e. Alzheimer and Parkin-
son’s disease, are usually not inherited diseases of monoge-
netic origin and cannot currently be treated by a gene correc-
tion approach. Instead, gene therapy approaches based on 
neurotrophic factor delivery, aiming to halt or reduce neu-
ronal cell death, are envisaged. Specifically, nerve growth 
factor (NGF) has been delivered in the brain of patients with 
Alzheimer disease either via direct intracerebral injection of 
an AAV vector or via transplantation of genetically-modified 
cells [20] and neurturin, a member of the glial cell line-
derived neurotrophic factor (GDNF) family ligands, was 
administered to advanced Parkinson’s disease patients using 
an AAV vector [21]. Because adverse effects of uncontrolled 
delivery of neurotrophic factors have been described [22-24], 
the ability to modulate transgene expression is crucial for 
these applications [25, 26]. 
Several inducible or repressible genetic systems to regu-
late intracerebral delivery of GDNF, which is envisaged for 
the treatment of Parkinson’s disease [27] (https://clinical 
trials.gov/ct2/show/NCT01621581), have been described. In 
a preclinical study, the mifepristone-regulated Gene Switch 
system provided neuroprotective effects of GDNF at a clini-
cally-acceptable dose of mifepristone [28]. However, this 
system was tightly regulated only in a 2-vector configuration 
[29], which limits applicability and clinical feasibility. The 
rapamycin-regulated system also allowed tight regulation of 
GDNF transgene expression, but the level of expression was 
low when compared with expression driven by a constitu-
tively active promoter [30]. 
Efficient on/off kinetics with a single-cassette AAV-Tet-
Off vector in the rat brain has been demonstrated [31]. Com-
plete extinction of GDNF transgene expression required a 
dox concentration of ~0.3 g/ml in the blood plasma, which 
corresponds to a clinically-acceptable dose. However, a very 
high dose of viral vector, well above that approved in current 
clinical trials, was used in this study. Using an auto-regulated 
AAV-Tet-On vector containing the rtTA2
S
-M2 transactivator 
(AAV-tetbidi-On) [32], a transgene expression efficiency 
could be reached that was only slightly lower than the level 
obtained with a constitutively active CMV enhan-
cer/promoter [33]. GDNF delivered by this vector in the 
brain of rats injected with 6-hydroxydopamine to model 
Parkinson’s disease, enhanced the function of dopaminergic 
neurons and resulted in behavioral improvements. In this 
study, the vector dose injected into the rat brain was 5 x 10
8
 
viral genomes, which is approximately equivalent to 2 x 10
7
 
viral genomes/mm
3
, the dose approved for the AAV-
neurturin clinical trial [34]. However, this and other studies 
[35] demonstrated that daily administration of a very high 
dox dose was required to induce rtTA2
S
-M2 driven transgene 
expression in the brain, which is mainly due to the blood-
brain barrier that causes a relatively low dox concentration in 
the cerebrospinal fluid (CSF) [36-38]. For example, in the 
rat/AAV-tetbidi-On study, administration of 600 mg/l dox in 
drinking water, which resulted in a dox concentration of ~5.3 
g/ml in blood and ~0.4 g/ml in CSF, was required to acti-
vate gene expression in the brain (unpublished data). Con-
sidering the putative toxic side effects of dox, long-term ad-
ministration of high dox doses should however be avoided. 
Therefore, new rtTA variants that are more active at lower 
dox levels are desirable. Because of the antibiotic activity of 
dox, such new rtTAs should preferably be active at sub-
antimicrobial dox doses that do not elicit adverse effects 
(such as affecting the gut flora) or lead to antibiotic resis-
tance. Brain applications of the Tet-On system could also 
benefit from rtTAs that are responsive to the tetracycline-
derivative minocycline (Mc), because Mc has an increased 
bioavailability and a greater lipophilicity, which results in a 
better tissue penetration [39]. In addition, Mc and dox ex-
hibit anti-inflammatory properties which could be of interest 
when treating neurodegenerative diseases [40, 41]. 
4. A DOX-CONTROLLED HIV-1 VARIANT AS A 
TOOL TO IMPROVE THE Tet-ON SYSTEM 
We used the Tet-On system to generate an HIV-1 variant 
that replicates exclusively in the presence of dox [42]. The 
construction of this unique virus and optimization of the Tet-
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On system by means of spontaneous virus evolution will be 
described in detail below. This conditionally replicating vi-
rus was also proposed as a novel approach toward a safe 
live-attenuated HIV vaccine, a topic that will be introduced 
first.  
4.1. Live-attenuated HIV Vaccine 
Live-attenuated virus (LAV) variants have proven to be 
an effective vaccine strategy against several viral diseases 
(e.g. small pox, polio, measles). The principle of a LAV vac-
cine is that the attenuated, non-pathogenic virus can replicate 
to a limited extent, which does not cause disease, but elicits a 
potent immune response that protects against a subsequent 
challenge with the wild-type, pathogenic virus. Live-
attenuated human immunodeficiency virus (HIV) variants 
have also been considered as vaccine for the protection of 
humans against HIV infection. Because such studies are not 
possible in humans, the animal model of simian immunode-
ficiency virus (SIV) infection in macaques was used. Attenu-
ated virus strains were constructed by deletion of accessory 
viral functions that stimulate in vivo replication, but are not 
absolutely required for virus replication, like the nef gene 
and particular long-terminal repeat (LTR) promoter domains. 
Vaccination of macaques with attenuated, non-pathogenic 
SIV strains did indeed induce effective protection against a 
challenge with wild-type, pathogenic SIV [43-45]. However, 
SIV, like HIV and other retroviruses, stably integrates in the 
genome of target cells and is never cleared upon infection. 
Because of this persistence, in combination with continuous 
low-level virus replication and the error-prone viral replica-
tion machinery, the attenuated vaccine virus can revert to 
virulence by the accumulation of mutations that improve 
replication. Evolution of the vaccine virus to a pathogenic 
variant did indeed cause disease in a minority of the vacci-
nated animals [46-49]. Similar observations with HIV con-
firmed the genetic instability of attenuated virus strains. For 
instance, an HIV3 variant with deletions in nef, vpr and 
LTR regained replication capacity in long-term cell culture 
infections by acquisition of compensatory mutations else-
where in the viral genome [50]. There is also some in vivo 
evidence as some of the long-term survivors of the Sydney 
Blood Bank Cohort, all infected with a naturally Nef-deleted 
HIV-1 variant, did eventually progress to AIDS [51]. The 
enormous evolutionary capacity of HIV poses a serious 
safety risk for the application of live-attenuated HIV-based 
vaccines in humans. Such undesirable evolution of the vac-
cine virus can be prevented by blocking continuous replica-
tion of the attenuated virus after vaccination using the Tet-
On system. 
4.2. A Conditionally Replicating HIV Variant 
To improve the safety of live-attenuated HIV vaccine 
candidates, we and others previously presented a condition-
ally replicating HIV variant, with replication that can be 
switched on and off at will by the administration and re-
moval of an exogenous effector, respectively [42, 52-55]. In 
this approach, the effector-dependence feature (on/off 
switch) will make it possible to allow temporal replication of 
the vaccine virus to the extent needed for induction of pro-
tective immunity. Subsequent effector-withdrawal will stop 
viral replication, which should prevent evolution of the vac-
cine virus toward a pathogenic variant. We used the Tet-On 
system to construct a conditionally replicating HIV-1 variant 
that was named HIV-rtTA. HIV-1 transcription and gene-
expression are normally driven by the 5’ LTR promoter and 
stimulated by binding of the viral Tat protein to the transact-
ing responsive (TAR) RNA element that is present at the 5’ 
end of the nascent viral transcripts (Fig. 3A). This auto-
regulatory loop results in the production of high levels of 
RNA and protein to support virus replication. In HIV-rtTA, 
the Tat-TAR transcription activation mechanism was func-
tionally replaced by the rtTA-tetO components of the Tet-On 
system [42, 55]. The Tat-TAR mechanism was inactivated 
through mutations in the TAR sequence that prevent Tat 
binding and an amino acid substitution in Tat that prevents 
trans-activation of transcription (Fig. 3B). The Tet-On sys-
tem was integrated into the viral genome by replacing the 
accessory nef gene by the gene encoding the optimized 
rtTA2
S
-S2 variant and inserting tet operator (tetO) sites in 
the viral LTR promoter. In the presence of dox, rtTA will 
bind to the tetO-LTR promoter and activate viral transcrip-
tion. HIV-rtTA replication can thus be controlled by the ad-
ministration of dox (Fig. 3C). Dox-dependent HIV-rtTA 
replication was shown in T cell line infections in vitro, ex 
vivo in human lymphoid tissue [56] and in vivo in a human-
ized mouse model [57, 58]. Application in humans may re-
quire additional safety measures. For instance, we inserted a 
second drug-dependent control mechanism into HIV-rtTA 
[59]. Alternatively, one may consider deletion of the inte-
grase (IN) function, which will likely prevent persistence of 
the vaccine virus. A dox-controlled SIV-rtTA variant [60, 
61] was employed in vaccination studies in macaques to 
study whether continuous low-level replication of the vac-
cine virus is required for protection and to determine the 
protective correlates that are induced by an effective vaccine 
[62].  
4.3. Evolution of HIV-rtTA 
Genetic diversity is continuously generated during HIV 
replication, which is primarily due to the error-prone reverse 
transcription process. Faster replicating variants will subse-
quently be selected by outcompeting the original virus. Thus, 
the virus can rapidly evolve and enhance its replication ca-
pacity. We anticipated that during in vitro culturing of HIV-
rtTA in human T cell lines this designer virus may adapt the 
integrated components of the Tet-On system, which are 
largely derived from E. coli, for their new function to sup-
port virus replication in human cells.  
4.3.1. Optimization of the tetO-LTR Promoter Region 
We did frequently observe specific deletions in the viral 
tetO-LTR promoter [63, 64]. In several independent cultures, 
we observed deletion of 6 of the 8 introduced tetO elements, 
which was followed by a deletion of 14 or 15 nt in the spacer 
between the remaining tetO sites. Strikingly, the new spacing 
between the remaining tetO elements resembles the spacing 
between these sites in the original E. coli Tn10 element. The 
new 2tetO-LTR configuration significantly improved HIV-
rtTA replication. Analysis of the promoter activity revealed 
that 2tetO-LTR was less active than the original 8tetO-LTR 
and similarly active as the wild-type HIV-1 LTR, which in-
dicates that HIV-1 requires a fine-tuned level of transcription
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Fig. (3). The dox-dependent HIV-rtTA virus. (A) Transcription of wild-type HIV-1 is activated by the binding of the viral Tat protein to 
the TAR hairpin structure that is present at the 5’ end of nascent RNA transcripts. This Tat-TAR axis thus controls viral gene expression and 
replication. (B) In HIV-rtTA, Tat and TAR are inactivated by mutation and functionally replaced by the rtTA-tetO components of the Tet-On 
system, by insertion of the rtTA gene at the site of the nef gene and insertion of tetO sequences in the LTR-promoter region. Transcription of 
this HIV-1 variant is activated by the binding of rtTA to the tetO-LTR promoter. Because rtTA binds the tetO sites exclusively in the pres-
ence of dox, HIV-rtTA does not replicate in the absence of this effector. (C) Dox-controlled replication of HIV-rtTA strains with the original 
rtTA-2
S
-S2 gene (left panel) and the F86Y-mutated variant (right panel) in SupT1 T-cells at different dox-concentrations. Virus replication is 
monitored by measuring the viral capsid protein (CA-p24) in the culture supernatant. Reproduced from [67] (
©
 2004, the American Society 
for Biochemistry and Molecular Biology). 
for efficient replication. This modulation was perhaps trig-
gered by acquired mutations in rtTA that increased the tran-
scriptional activity (see section below). Alternatively, the 
tetO region may have been truncated because 8 copies of the 
tetO sequence may have a negative effect on virus replica-
tion. Sequence repeats can indeed trigger recombination 
events [65, 66] or cause aberrant folding of the viral RNA, 
which may reduce viral replication fitness. 
4.3.2. Optimization of rtTA 
We also observed mutations in the rtTA gene upon long 
term replication of HIV-rtTA. Initially, a Phe to Tyr substitu-
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tion was observed at amino acid position 86 (F86Y) in the 
TetR core domain (Fig. 4A), at a position that directly inter-
acts with Tc in the TetR-Tc crystal structure [67]. This muta-
tion coincided with an Ala to Thr substitution at position 209 
(A209T) in one of the minimal AD sequences. Subsequent 
analyses demonstrated that the F86Y mutation significantly 
improved HIV-rtTA replication, in particular al lower dox 
levels (Fig. 3C), whereas the A209T mutation had no effect. 
To test the impact in the context of the standard Tet-On sys-
tem, the capacity to activate transcription of Ptet-reporter 
constructs was measured in human cell lines transfected with 
rtTA-expressing and Ptet-luciferase plasmids. 
The F86Y mutation was found to increase the transcrip-
tional activity and dox-sensitivity of rtTA, whereas the 
A209T mutation had again no effect. Importantly, the muta-
tions did not affect the background transcriptional activity in 
the absence of dox. The rtTA activity and dox-sensitivity of 
rtTA
F86Y+A209T
 (named rtTA-V1; Fig. 2) was further in-
creased by introducing the S12G mutation that is typical for 
rtTA2
S
-M2. When compared with rtTA2
S
-S2, the new 
rtTA
S12G+F86Y+A209T
 variant (a.k.a. rtTA3 [68]) was 5-fold 
more active at high dox levels and required 25-fold less dox 
to be similarly active (25-fold more sensitive to dox). 
To further improve the Tet-On system by virus evolution, 
we started multiple cultures of HIV-rtTA-V1, which con-
tained both the improved rtTA-V1 gene and the optimized 
2tetO-LTR promoter configuration. Upon long term cultur-
ing, we identified several additional mutations in the TetR 
domain of the rtTA protein that were selected in independent 
cultures: a V9I substitution in the DBD; F67S, G138D and 
R171K substitutions at positions that do not directly bind Tc 
in the TetR-Tc crystal structure, but are in close proximity to 
the binding pocket and may indirectly influence binding of 
the effector; and an E157K substitution in a flexible loop 
region that was not solved in the crystal structure (V2-V6 
variants; Fig. 4). The V9I mutation appeared both as an indi-
vidual mutation (V2) and in combination with G138D, 
E157K or R171K (V7-V9). A combination of F67S and 
R171K was also observed (V10). Except for the V2 variant, 
the new variants demonstrated higher activity and dox sensi-
tivity than V1 when the capacity to activate pTet-driven re-
porter expression was analyzed (Fig. 4B). The V10 double 
 
Fig. (4). Optimization of the Tet-On system through virus evolution. (A) Amino acid substitutions observed in rtTA-2
S
-S2 (wild-type) 
upon long-term culturing of HIV-rtTA in human SupT1 T-cells. (B) The transcriptional activity (at 1000 ng/ml dox) and dox-sensitivity of 
the wild-type, naturally evolved (V1-V10) and constructed (V11-V18) rtTA variants was measured in HeLa X1/6 cells that contain chromo-
somally integrated copies of the Ptet-luciferase reporter construct. The wild-type rtTA activity at 1000 ng/ml dox was set at 100%. The activ-
ity measured at different dox concentrations was used to calculate the dox concentration that each rtTA variant needs to reach an activity 
comparable to that of the wild-type rtTA at 1000 ng/ml dox. These concentrations are indicated between brackets in the right panel (nd, not 
determined), and were used to calculate the dox-sensitivity for each rtTA variant (dox-sensitivity of wild-type rtTA set at 1). *, V1-V18 carry 
the F86Y and A209T mutations in addition to the shown mutations. Reproduced from [69] (
©
 2006, Zhou et al.). 
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mutant showed the highest activity and dox-sensitivity [69]. 
Several additional rtTA variants were constructed in which 
the observed mutations were combined (V11-V18; Fig. 4B). 
The triple mutant V16, in which the V10 mutations were 
combined with V9I, demonstrated the highest activity and 
dox-sensitivity. V16 was seven-fold more active at high dox 
levels and 100-fold more sensitive to dox than rtTA2
S
-S2, 
and showed no activity without dox when the activity was 
measured upon transfection of rtTA plasmids into cells with 
an integrated pTet-reporter construct (Fig. 4B). The muta-
tions also improved the activity with other non-dox effectors 
and restored the responsiveness to Tc [69]. The mutations 
did not affect the intracellular rtTA protein level, indicating 
an improved intrinsic rtTA activity and effector-sensitivity 
[67, 69]. The improved rtTA characteristics likely result 
from an improved interaction with the effector molecule 
and/or the tetO DNA elements. 
5. COMPARISON OF NOVEL Tet-ON SYSTEMS 
To identify which Tet-On system is optimal for specific 
cell culture applications, we recently compared the opti-
mized rtTA variants. For this, we tested the rtTA2
s
-M2 (ab-
breviated as M2; a.k.a. Tet-On advanced, Clontech), V10 
(a.k.a. Tet-On 3G) and V16 variants in several experimental 
settings in some frequently used cell types. 
5.1. Transiently Transfected Cells 
When rtTA activity was measured in cells upon transient 
transfection with the rtTA and Ptet-reporter plasmids (Fig. 
5A), we consistently observed highest dox-induced activity 
for the V16 variant, intermediate activity for V10 and lowest 
activity for M2 (Fig. 5B) [70]. V16 activated reporter ex-
pression at very low dox levels, confirming its extreme dox 
sensitivity. However, V16 caused very low, but detectable 
background expression in the absence of dox, which be-
comes particularly noticeable when high amounts of DNA 
were transfected. M2 also demonstrated a low level of back-
ground activity, although to a lesser extent than V16. The 
V10 variant did not show any background activity and, as a 
consequence, showed superior fold-induction rates (Fig. 5C). 
Therefore, V10 will be the optimal system for most applica-
tions involving transiently transfected cells and other situa-
tions where the Tet-On components will be present epi-
somally at relatively high concentrations (Fig. 6). When high 
transcriptional activity at low dox levels is required, for ex-
ample when the cells do not tolerate a high dox level, the 
dox-sensitive V16 variant may be preferred.  
5.2. Stably Transduced Cells 
Also when the rtTA and Ptet-reporter cassettes were sta-
bly integrated in the cellular genome through lentiviral vec-
tor transduction (Fig. 5D), V16 demonstrated highest, V10 
intermediate and M2 lowest dox-induced activity (Fig. 5E) 
[70]. Since the background activity of all rtTAs was simi-
larly low, V16 also showed the highest fold-induction, 
whereas V10 showed intermediate and M2 the lowest fold-
induction (Fig. 5F). When gene expression in the transduced 
cells was reactivated by dox administration after a latency 
period without dox, V16 consistently showed more robust 
induction of gene expression than V10 and M2, resulting in 
the reactivation of gene expression in a larger fraction of the 
transduced cells (Fig. 5G) or in reactivation at a lower dox 
concentration (Fig. 5H), depending on the cell type. These 
results indicate that the integrated reporter gene construct is 
sensitive to transcriptional silencing and variegation effects 
upon dox withdrawal, which are likely caused by the cellular 
DNA sequences surrounding the integration site [71]. Ap-
parently, the highly active V16 overcomes this gene repres-
sion more efficiently than the less active V10 and M2 vari-
ants. With this high reactivation capacity of V16, more labo-
rious procedures to obtain high transgene expressing cells, 
such as the selection of clonal cell lines, may not be needed. 
Because of its high activity, dox-sensitivity and robust 
reactivation capacity, V16 will be the optimal variant for 
most applications in which the gene constructs are stably 
integrated in the cellular genome (Fig. 6). The high dox-
sensitivity of V16 also allowed us to develop a sensitive bio-
assay for measuring the dox concentration in biological sam-
ples [72].  
6. OPTIMAL Tet-ON SYSTEM FOR IN VIVO APPLI-
CATIONS 
The direct comparison of the new Tet-On systems was 
limited to the in vitro cell culture setting. In vivo application 
of the systems can be complicated by immune responses 
against rtTA, as reported in rodents and non-human primates 
[73-78]. These immune responses, both cellular and hu-
moral, are dependent on the target tissue and vector delivery 
route (reviewed in [78]). The amino acid substitutions typical 
for M2, V10 and V16 do not affect any of the known HLA-
A*0201 restricted CTL epitopes in rtTA [73]. In transgenic 
mice, toxic side-effects of tTA and rtTA have also been re-
ported [79-83]. The severity of these effects depends on the 
genetic background of the animal and possibly also on the 
(r)tTA version used. For example, the complete VP16 AD in 
the original versions may be more toxic to cells due to 
squelching effects than the minimized AD in later versions. 
The S12G and V9I mutations in the DBD of M2 and V16, 
respectively, may affect the interaction of rtTA with cellular 
promoter regions and thus influence cellular gene expres-
sion, but whether an up or down effect is induced remains to 
be determined. Another obvious issue to take into considera-
tion is that a more dox-sensitive rtTA variant, like V16, may 
demonstrate prolonged activity when the dox level drops 
after dox-withdrawal [84]. These limitations of the model 
system should be recognized and appropriate controls should 
be included in the analysis. Which rtTA variant will be opti-
mal in complex in vivo situations is currently unknown and 
may depend on the cell and tissue type that is targeted for 
transgene expression. If only relatively low dox levels can be 
reached, for example in the brain due to the blood-brain bar-
rier, the ultra dox-sensitive V16 variant will likely be the 
best candidate. Recent studies successfully applied V16 to 
control transgene expression in mice [85, 86] and non-human 
primates [62, 87]. In a direct comparison, V16 outperformed 
the M2 variant when used to control the expression of an 
AAV-delivered GDNF gene in the rat brain, resulting in 
therapeutically-relevant biological effects of the transgene at 
clinically-approved sub-antimicrobial dox doses [88]. 
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Fig. (5). Comparison of rtTA variants in transiently transfected and stably transduced cells. (A-C) Different human cell lines (HeLa 
cervix carcinoma and HEK293 embryonal kidney cells) were transfected with low and high amounts of CMV enhancer/promoter-driven 
PCMV-rtTA (either rtTA2
S
-M2 [M2], rtTA-V10 or rtTA-V16) and dox-rtTA activated Ptet-luciferase constructs (constructs shown in A), and 
cultured in the presence of 0 to 1000 ng/ml dox. (B) The luciferase level measured 2 days after transfection reflects the rtTA activity. The 
activity of M2 at 1000 ng/ml dox was set at 100%. The average of the values obtained for different experimental conditions (different cells 
and different amounts of DNA) [70] is shown to illustrate the differences between the rtTA variants (no, transfection of cells with the empty 
vector instead of the rtTA plasmid). The original data for each cell line and amount of DNA are presented in [70]. (C) Fold induction levels, 
calculated as the ratio between the rtTA activity at the indicated dox concentration and the activity in the absence of dox (0 ng/ml). (D-H) 
Different human cell lines (SupT1, HeLa, HepG2 hepatocellular carcinoma and SJNB-8 neuroblastoma cells) were transduced with a lentivi-
ral vector containing Ptet-d2EGFP and PCMV-rtTA (M2, V10 or V16) cassettes (construct shown in D). Cells were cultured with dox for 3 
days. GFP-positive (GFP
+
) cells were sorted and cultured without dox for 6 days to switch off GFP expression. The isolated transduced cells 
were subsequently cultured with different dox concentrations for 3 days, after which the intracellular GFP level was analyzed. (E) The mean 
fluorescent intensity (MFI) of the total cell population reflects the rtTA activity. The activity of M2 at 1000 ng/ml dox was set at 100%. The 
average of the values obtained with the different cells (original data published in [70]) is shown to illustrate the differences between the rtTA 
variants. (F) Fold induction levels, calculated as the ratio between the MFI at the indicated dox concentration and the MFI in the absence of 
dox (0 ng/ml). (G) The average percentage of GFP
+
 cells measured for the SupT1, HeLa and SJNB-8 cells that express GFP predominantly in 
a threshold mode (i.e. increasing the dox concentration activated GFP expression in more cells, rather than that it increased the fluorescence 
intensity of the GFP
+
 cells [89]; original data published in [70]). (H) The percentage of GFP
+
 cells measured for HepG2 cells that express 
GFP predominantly in a graded mode (i.e. increasing the dox concentration predominantly increased the fluorescence intensity of the GFP
+
 
cells [89]). 
0
100
200
300
400
500
600
700
0 1 10 100 1000
M2
V10
V16
no
0
1
10
100
1000
0 1 10 100 1000
M2
V10
V16
no
10
100
1000
1 10 100 1000
M2
V10
V16
0
5
10
15
20
25
30
35
40
1 10 100 1000
M2
V10
V16
0
10
20
30
40
50
60
70
80
1 10 100 1000
M2
V10
V16
0
10
20
30
40
50
60
70
80
1 10 100 1000
M2
V10
V16
A
B C
D
HG
FE
PREPCMVPtetcPPTRSV R U5 LTR (SIN)RRE rtTAEGFP
PCMV PtetrtTA luciferase
dox (ng/ml) dox (ng/ml)
dox (ng/ml) dox (ng/ml)
dox (ng/ml) dox (ng/ml)

a
ct
iv
ity
(%
)
fo
ld
in
du
ct
io
n
M
FI
 (%
)
fo
ld
in
du
ct
io
n
%
G
FP
+
(th
res
ho
ld
m
o
de
)
%
G
FP
+
(gr
ad
ed
m
o
de
)


Tet-On Systems For Doxycycline-inducible Gene Expression Current Gene Therapy, 2016, Vol. 16, No. 3    165 
 
Fig. (6). Identification of the optimal Tet-On system for different applications. Direct comparison of the activity of the rtTA-2
S
-M2 (M2), 
rtTA-V10 and rtTA-V16 variants in transiently transfected and stably transduced cells (as shown in Fig. 5) revealed their quality with respect 
to different parameters. +, good; ++, better; +++, best; n/a, not applicable. 
CONFLICT OF INTEREST 
Authors declare having potential competing financial in-
terests. The rtTA V10 and V16 variants have been filed in 
patent WO2007058527. 
ACKNOWLEDGEMENTS 
The HIV-rtTA and Tet-On research in our lab was spon-
sored by research grants from the AIDS Fonds (grant 
2005022 and 2007028), the Technology Foundation STW 
(applied science division of the Netherlands Organisation for 
Scientific Research NWO and the technology program of the 
Ministry of Economic Affairs, Utrecht, the Netherlands) and 
the EU FP7 Marie Curie IAPP (Industry Academia Partner-
ships and Pathways) BrainVectors (contract 286071). 
REFERENCES 
[1] Fussenegger M. The impact of mammalian gene regulation con-
cepts on functional genomic research, metabolic engineering, and 
advanced gene therapies. Biotechnol Prog 2001; 17(1): 1-51. 
[2] Gossen M, Bujard H. Tetracyclines in the control of gene expres-
sion in eukaryotes. In: Nelson M, Hillen W, Greenwald RA, Eds. 
Tetracyclines in biology, chemistry and medicine. Birkhäuser Ver-
lag: Basel 2001; pp. 139-57. 
[3] Baron U, Bujard H. Tet repressor-based system for regulated gene 
expression in eukaryotic cells: principles and advances. Methods 
Enzymol 2000; 327: 401-21. 
[4] Berens C, Hillen W. Gene regulation by tetracyclines. Constraints 
of resistance regulation in bacteria shape TetR for application in 
eukaryotes. Eur J Biochem 2003; 270(15): 3109-21. 
[5] Roberts MC. Update on acquired tetracycline resistance genes. 
FEMS Microbiol Lett 2005; 245(2): 195-203. 
[6] Chopra I, Roberts M. Tetracycline antibiotics: mode of action, 
applications, molecular biology, and epidemiology of bacterial re-
sistance. Microbiol Mol Biol Rev 2001; 65(2): 232-60. 
[7] Bertram R, Hillen W. The application of Tet repressor in prokary-
otic gene regulation and expression. Microb Biotechnol 2008; 1(1): 
2-16. 
[8] Meier I, Wray LV, Hillen W. Differential regulation of the Tn10-
encoded tetracycline resistance genes tetA and tetR by the tandem 
tet operators O1 and O2. EMBO J 1988; 7(2): 567-72. 
[9] Hillen W, Berens C. Mechanisms underlying expression of Tn10 
encoded tetracycline resistance. Annu Rev Microbiol 1994; 48: 
345-69. 
[10] Nguyen TN, Phan QG, Duong LP, et al. Effects of carriage and 
expression of the Tn10 tetracycline-resistance operon on the fitness 
of Escherichia coli K12. Mol Biol Evol 1989; 6(3): 213-25. 
[11] Gossen M, Bujard H. Tight control of gene expression in mammal-
ian cells by tetracycline-responsive promoters. Proc Natl Acad Sci 
USA 1992; 89(12): 5547-51. 
[12] Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation 
by tetracyclines in mammalian cells. Science 1995; 268: 1766-9. 
[13] Loew R, Heinz N, Hampf M, et al. Improved Tet-responsive pro-
moters with minimized background expression. BMC Biotechnol 
2010; 10: 81. 
[14] Agha-Mohammadi S, O'Malley M, Etemad A, et al. Second-
generation tetracycline-regulatable promoter: repositioned tet op-
erator elements optimize transactivator synergy while shorter 
minimal promoter offers tight basal leakiness. J Gene Med 2004; 
6(7): 817-28. 
[15] Urlinger S, Baron U, Thellmann M, et al. Exploring the sequence 
space for tetracycline dependent transcriptional activators: novel 
mutations yield expanded range and sensitivity. Proc Natl Acad Sci 
USA 2000; 97: 7963-8. 
[16] Baron U, Gossen M, Bujard H. Tetracycline-controlled transcrip-
tion in eukaryotes: novel transactivators with graded transactivation 
potential. Nucleic Acids Res 1997; 25(14): 2723-9. 
[17] Moullan N, Mouchiroud L, Wang X, et al. Tetracyclines disturb 
mitochondrial function across eukaryotic models: A call for caution 
in biomedical research. Cell Rep 2015; 10(10): 1681-91. 
[18] High KA. The gene therapy journey for hemophilia: are we there 
yet? Blood 2012; 120(23): 4482-7. 
[19] McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in 
a phase I study for Canavan disease. J Gene Med 2006; 8(5): 577-
88. 
[20] Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene 
therapy: Activation of neuronal responses in alzheimer disease. 
JAMA Neurol 2015; 72(10): 1139-47. 
[21] Marks WJ, Jr., Bartus RT, Siffert J, et al. Gene delivery of AAV2-
neurturin for Parkinson's disease: a double-blind, randomised, con-
trolled trial. Lancet Neurol 2010; 9(12): 1164-72. 
[22] Schlichtenbrede FC, MacNeil A, Bainbridge JW, et al. Intraocular 
gene delivery of ciliary neurotrophic factor results in significant 
loss of retinal function in normal mice and in the Prph2Rd2/Rd2 
model of retinal degeneration. Gene Ther 2003; 10(6): 523-7. 
[23] Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-
blind trial of glial cell line-derived neurotrophic factor (GDNF) in 
PD. Neurology 2003; 60(1): 69-73. 
[24] Manfredsson FP, Tumer N, Erdos B, et al. Nigrostriatal rAAV-
mediated GDNF overexpression induces robust weight loss in a rat 
model of age-related obesity. Mol Ther 2009; 17(6): 980-91. 
[25] Chtarto A, Bockstael O, Tshibangu T, et al. A next step in adeno-
associated virus-mediated gene therapy for neurological diseases: 
regulation and targeting. Br J Clin Pharmacol 2013; 76(2): 217-32. 
[26] Manfredsson FP, Bloom DC, Mandel RJ. Regulated protein ex-
pression for in vivo gene therapy for neurological disorders: Pro-
gress, strategies, and issues. Neurobiol Dis 2012; 48(2): 212-21. 
[27] Su X, Kells AP, Huang EJ, et al. Safety evaluation of AAV2-
GDNF gene transfer into the dopaminergic nigrostriatal pathway in 
aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009; 
20(12): 1627-40. 
[28] Tereshchenko J, Maddalena A, Bahr M, et al. Pharmacologically 
controlled, discontinuous GDNF gene therapy restores motor func-
tion in a rat model of Parkinson's disease. Neurobiol Dis 2014; 65: 
35-42. 
[29] Maddalena A, Tereshchenko J, Bahr M, et al. Adeno-associated 
virus-mediated, mifepristone-regulated transgene expression in the 
brain. Mol Ther Nucleic Acids 2013; 2: e106. 
[30] Hadaczek P, Beyer J, Kells A, et al. Evaluation of an AAV2-based 
rapamycin-regulated glial cell line-derived neurotrophic factor 
(GDNF) expression vector system. PLoS One 2011; 6(11): e27728. 
[31] Manfredsson FP, Burger C, Rising AC, et al. Tight Long-term 
dynamic doxycycline responsive nigrostriatal GDNF using a single 
rAAV vector. Mol Ther 2009; 17(11): 1857-67. 
construct rtTA activity dox-sensitivity background fold-induction reactivation
episomal
(transient 
transfection)
M2 + + yes + n/a
V10 ++ ++ no +++ n/a
V16 +++ +++ yes + n/a
integrated
(lentiviral 
transduction)
M2 + + no + +
V10 ++ ++ no ++ ++
V16 +++ +++ no +++ +++
166    Current Gene Therapy, 2016, Vol. 16, No. 3 Das et al. 
[32] Chtarto A, Yang X, Bockstael O, et al. Controlled delivery of glial 
cell line-derived neurotrophic factor by a single tetracycline-
inducible AAV vector. Exp Neurol 2007; 204(1): 387-99. 
[33] Bockstael O, Chtarto A, Wakkinen J, et al. Differential transgene 
expression profiles in rat brain, using rAAV2/1 vectors with tetra-
cycline-inducible and cytomegalovirus promoters. Hum Gene Ther 
2008; 19(11): 1293-305. 
[34] Gasmi M, Brandon EP, Herzog CD, et al. AAV2-mediated delivery 
of human neurturin to the rat nigrostriatal system: long-term effi-
cacy and tolerability of CERE-120 for Parkinson's disease. Neuro-
biol Dis 2007; 27(1): 67-76. 
[35] Vogel R, Amar L, Thi AD, et al. A single lentivirus vector medi-
ates doxycycline-regulated expression of transgenes in the brain. 
Hum Gene Ther 2004; 15(2): 157-65. 
[36] Karlsson M, Hammers S, Nilsson-Ehle I, et al. Concentrations of 
doxycycline and penicillin G in sera and cerebrospinal fluid of pa-
tients treated for neuroborreliosis. Antimicrob Agents Chemother 
1996; 40(5): 1104-7. 
[37] Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycy-
cline into the cerebrospinal fluid of patients with latent or neuro-
syphilis. Antimicrob Agents Chemother 1985; 28(2): 347-8. 
[38] Centlivre M, Zhou X, Pouw SM, et al. Autoregulatory lentiviral 
vectors allow multiple cycles of doxycycline-inducible gene ex-
pression in human hematopoietic cells in vivo. Gene Ther 2010; 
17(1): 14-25. 
[39] Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and 
minocycline. Clin Pharmacokinet 1988; 15(6): 355-66. 
[40] Blum D, Chtarto A, Tenenbaum L, et al. Clinical potential of mi-
nocycline for neurodegenerative disorders. Neurobiol Dis 2004; 
17(3): 359-66. 
[41] McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg im-
mediate-release/10 mg delayed-release beads): anti-inflammatory 
dose in rosacea. Am J Clin Dermatol 2010; 11(3): 217-22. 
[42] Verhoef K, Marzio G, Hillen W, et al. Strict control of human 
immunodeficiency virus type 1 replication by a genetic switch: Tet 
for Tat. J Virol 2001; 75(2): 979-87. 
[43] Johnson RP. Live attenuated AIDS vaccines: hazards and hopes. 
Nat Med 1999; 5: 154-5. 
[44] Desrosiers RC. Prospects for live attenuated HIV. Nat Med 1998; 
4: 982. 
[45] Mills J, Desrosiers R, Rud E, et al. Live attenuated HIV vaccines: 
proposal for further research and development. AIDS Res Hum 
Retroviruses 2000; 16: 1453-61. 
[46] Baba TW, Jeong YS, Penninck D, et al. Pathogenicity of live, 
attenuated SIV after mucosal infection of neonatal macaques. Sci-
ence 1995; 267: 1820-5. 
[47] Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply 
deleted simian immunodeficiency virus causes AIDS in infant and 
adult macaques. Nat Med 1999; 5: 194-203. 
[48] Chakrabarti LA, Metzner KJ, Ivanovic T, et al. A truncated form of 
Nef selected during pathogenic reversion of simian immunodefi-
ciency virus SIVmac239Deltanef increases viral replication. J Virol 
2003; 77(2): 1245-56. 
[49] Whatmore AM, Cook N, Hall GA, et al. Repair and evolution of 
nef in vivo modulates simian immunodeficiency virus virulence. J 
Virol 1995; 69: 5117-23. 
[50] Berkhout B, Verhoef K, van Wamel JLB, et al. Genetic instability 
of live-attenuated HIV-1 vaccine strains. J Virol 1999; 73: 1138-
45. 
[51] Zaunders J, Dyer WB, Churchill M. The Sydney Blood Bank Co-
hort: implications for viral fitness as a cause of elite control. Curr 
Opin HIV AIDS 2011; 6(3): 151-6. 
[52] Smith SM, Khoroshev M, Marx PA, et al. Constitutively dead, 
conditionally live HIV-1 genomes. Ex vivo implications for a live 
virus vaccine. J Biol Chem 2001; 276(34): 32184-90. 
[53] Berkhout B, Marzio G, Verhoef K. Control over HIV-1 replication 
by an antibiotic; a novel vaccination strategy with a drug-
dependent virus. Virus Res 2002; 82(1-2): 103-8. 
[54] Das AT, Zhou X, Vink M, et al. Conditional live virus as a novel 
approach towards a safe live attenuated HIV vaccine. Expert Rev 
Vaccines 2002; 1(3): 293-301. 
[55] Das AT, Verhoef K, Berkhout B. A conditionally replicating virus 
as a novel approach toward an HIV vaccine. Methods Enzymol 
2004; 388: 359-79. 
[56] Kiselyeva Y, Ito Y, Lima RG, et al. Depletion of CD4 T lympho-
cytes in human lymphoid tissue infected ex vivo with doxycycline-
dependent HIV-1. Virology 2004; 328(1): 1-6. 
[57] Legrand N, van der Velden GJ, Fang RH, et al. A doxycycline-
dependent human immunodeficiency virus type 1 replicates in vivo 
without inducing CD4+ T-cell depletion. J Gen Virol 2012; 93(9): 
2017-27. 
[58] van der Velden YU, Kleibeuker W, Harwig A, et al. Construction 
of Nef-positive doxycycline-dependent HIV-1 variants using bicis-
tronic expression elements. Virology 2016; 488: 96-107. 
[59] Das AT, Baldwin CE, Vink M, et al. Improving the safety of a 
conditional-live human immunodeficiency virus type 1 vaccine by 
controlling both gene expression and cell entry. J Virol 2005; 
79(6): 3855-8. 
[60] Das AT, Klaver B, Harwig A, et al. Construction of a doxycycline-
dependent simian immunodeficiency virus reveals a non-
transcriptional function of Tat in viral replication. J Virol 2007; 
81(20): 11159-69. 
[61] Das AT, Klaver B, Centlivre M, et al. Optimization of the doxycy-
cline-dependent simian immunodeficiency virus through in vitro 
evolution. Retrovirology 2008; 5: 44. 
[62] Manoussaka MS, Berry N, Ferguson D, et al. Conditionally-live 
attenuated SIV upregulates global T effector memory cell fre-
quency under replication permissive conditions. Retrovirology 
2013; 10(1): 59. 
[63] Marzio G, Verhoef K, Vink M, et al. In vitro evolution of a highly 
replicating, doxycycline-dependent HIV for applications in vaccine 
studies. Proc Natl Acad Sci USA 2001; 98(11): 6342-7. 
[64] Marzio G, Vink M, Verhoef K, et al. Efficient human immunodefi-
ciency virus replication requires a fine-tuned level of transcription. 
J Virol 2002; 76(6): 3084-8. 
[65] Moumen A, Polomack L, Roques B, et al. The HIV-1 repeated 
sequence R as a robust hot-spot for copy-choice recombination. 
Nucleic Acids Res 2001; 29(18): 3814-21. 
[66] Pathak VK, Temin HM. Broad spectrum of in vivo forward muta-
tions, hypermutations, and mutational hotspots in a retroviral shut-
tle vector after a single replication cycle: substitutions, frameshifts, 
and hypermutations. Proc Natl Acad Sci USA 1990; 87: 6019-23. 
[67] Das AT, Zhou X, Vink M, et al. Viral evolution as a tool to im-
prove the tetracycline-regulated gene expression system. J Biol 
Chem 2004; 279(18): 18776-82. 
[68] Markusic D, Oude-Elferink R, Das AT, et al. Comparison of single 
regulated lentiviral vectors with rtTA expression driven by an 
autoregulatory loop or a constitutive promoter. Nucleic Acids Res 
2005; 33(6): e63. 
[69] Zhou X, Vink M, Klaver B, et al. Optimization of the Tet-On sys-
tem for regulated gene expression through viral evolution. Gene 
Ther 2006; 13(19): 1382-90. 
[70] Das AT, Zhou X, Metz SW, et al. Selecting the optimal Tet-On 
system for doxycycline-inducible gene expression in transiently 
transfected and stably transduced mammalian cells. Biotechnol J 
2016; 11(1): 71-9. 
[71] Ellis J. Silencing and variegation of gammaretrovirus and lentivirus 
vectors. Hum Gene Ther 2005; 16(11): 1241-6. 
[72] Kleibeuker W, Zhou X, Centlivre M, et al. A sensitive cell-based 
assay to measure the doxycycline concentration in biological sam-
ples. Hum Gene Ther 2009; 20(5): 524-30. 
[73] Ginhoux F, Turbant S, Gross DA, et al. HLA-A*0201-restricted 
cytolytic responses to the rtTA transactivator dominant and cryptic 
epitopes compromise transgene expression induced by the tetracy-
cline on system. Mol Ther 2004; 10(2): 279-89. 
[74] Lena AM, Giannetti P, Sporeno E, et al. Immune responses against 
tetracycline-dependent transactivators affect long-term expression 
of mouse erythropoietin delivered by a helper-dependent adenovi-
ral vector. J Gene Med 2005; 7(8): 1086-96. 
[75] Favre D, Blouin V, Provost N, et al. Lack of an immune response 
against the tetracycline-dependent transactivator correlates with 
long-term doxycycline-regulated transgene expression in nonhu-
man primates after intramuscular injection of recombinant adeno-
associated virus. J Virol 2002; 76(22): 11605-11. 
[76] Latta-Mahieu M, Rolland M, Caillet C, et al. Gene transfer of a 
chimeric trans-activator is immunogenic and results in short-lived 
transgene expression. Hum Gene Ther 2002; 13(13): 1611-20. 
[77] Markusic DM, de Waart DR, Seppen J. Separating lentiviral vector 
injection and induction of gene expression in time, does not prevent 
an immune response to rtTA in rats. PLoS One 2010; 5(4): e9974. 
Tet-On Systems For Doxycycline-inducible Gene Expression Current Gene Therapy, 2016, Vol. 16, No. 3    167 
[78] Le Guiner C, Stieger K, Snyder RO, et al. Immune responses to 
gene product of inducible promoters. Curr Gene Ther 2007; 7(5): 
334-46. 
[79] McCloskey DT, Turnbull L, Swigart PM, et al. Cardiac transgene-
sis with the tetracycline transactivator changes myocardial function 
and gene expression. Physiol Genomics 2005; 22(1): 118-26. 
[80] Barton MD, Dunlop JW, Psaltis G, et al. Modified GFAP promoter 
auto-regulates tet-activator expression for increased transactivation 
and reduced tTA-associated toxicity. Brain Res Mol Brain Res 
2002; 101(1–2): 71-81. 
[81] Sisson TH, Hansen JM, Shah M, et al. Expression of the reverse 
tetracycline-transactivator gene causes emphysema-like changes in 
mice. Am J Respir Cell Mol Biol 2006; 34(5): 552-60. 
[82] Han HJ, Allen CC, Buchovecky CM, et al. Strain background 
influences neurotoxicity and behavioral abnormalities in mice ex-
pressing the tetracycline transactivator. J Neurosci 2012; 32(31): 
10574-86. 
[83] Morimoto M, Kopan R. rtTA toxicity limits the usefulness of the 
SP-C-rtTA transgenic mouse. Dev Biol 2009; 325(1): 171-8. 
[84] Anders K, Buschow C, Charo J, et al. Depot formation of doxycy-
cline impairs Tet-regulated gene expression in vivo. Transgenic Res 
2012; 21(5): 1099-107. 
[85] Sooksawate T, Isa K, Matsui R, et al. Viral vector-mediated selec-
tive and reversible blockade of the pathway for visual orienting in 
mice. Front Neural Circuits 2013; 7: 162. 
[86] Tian X, Wang G, Xu Y, et al. An improved tet-on system for gene 
expression in neurons delivered by a single lentiviral vector. Hum 
Gene Ther 2009; 20(2): 113-23. 
[87] Kinoshita M, Matsui R, Kato S, et al. Genetic dissection of the 
circuit for hand dexterity in primates. Nature 2012; 487(7406): 
235-8. 
[88] Chtarto A, Humbert-Claude M, Bockstael O, et al. A regulatable 
AAV vector mediating GDNF biological effects at clinically-
approved sub-antimicrobial doxycycline doses. Mol Ther Methods 
Clin Dev 2016; 5: 16027. 
[89] Heinz N, Hennig K, Loew R. Graded or threshold response of the 
tet-controlled gene expression: all depends on the concentration of 
the transactivator. BMC Biotechnol 2013; 13: 5. 
 
